[1] 魏亚明,桂嵘,王秋实,等.血小板抗体检测专家共识[J]. 临床输血与检验,2020,22(1):1-5.
[2] ZHI L,CHI X,GELDERMAN M P,et al.Activation of platelet protein kinase C by ultraviolet light B mediates platelet transfusion-related acute lung injury in a two-event animal model[J]. Transfusion,2013,53(4):722-731.
[3] BELIZAIRE R,MAKAR R S.Non-alloimmune mechanisms of thrombocytopenia and refractoriness to platelet transfusion[J].Transfus Med Rev,2020,34(4):242-249.
[4] DOUGHTY H A,MURPHY M F,METCALFE P,et al.Relative importance of immune and non-immune causes of platelet refractoriness[J]. Vox Sang,1994,66(3):200-205.
[5] CHOCKALINGAM P,SACHER R A.Management of patients refractory to platelet transfusion[J].J Infus Nurs,2007,30(4):220-225.
[6] JUSKEWITCH J E,NORGAN A P,DE GOEY S R,et al. How do I ··· manage the platelet transfusion-refractory patient?[J]. Transfusion,2017,57(12):2828-2835.
[7] ESTCOURT L J,BIRCHALL J,ALLARD S,et al.Guidelines for the use of platelet transfusions[J]. Br J Haematol,2017,176(3):365-394.
[8] KAUFMAN R M,DJULBEGOVIC B,GERNSHEIMER T,et al.Platelet transfusion:a clinical practice guideline from the AABB[J]. Ann Intern Med,2015,162(3):205-213.
[9] NAHIRNIAK S,SLICHTER S J,TANAEL S,et al.Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia[J]. Transfus Med Rev,2015,29(1):3-13.
[10] 傅启华,王静.紧急抢救时ABO血型不相同血小板输注专家共识[J].中国输血杂志,2017,30(7):666-667.
[11] 何吉. 血小板配型及相容性输注的专家共识[J]. 浙江医学,2021,43(13):1367-1371.
[12] 国家卫生健康委员会.输血相容性检测标准:WS/T 794-2022[S]. 北京:中国标准出版社,2022.
[13] STANWORTH S J,NAVARRETE C,ESTCOURT L,et al.Platelet refractoriness-practical approaches and ongoing dilemmas in patient management[J]. Br J Haematol,2015,171(3):297-305.
[14] PRODGER C F,RAMPOTAS A,ESTCOURT L J,et al.Platelet transfusion:alloimmunization and refractoriness[J]. Semin Hematol,2020,57(2):92-99.
[15] SARIS A,PAVENSKI K.Human leukocyte antigen alloimmunization and alloimmune platelet refractoriness[J]. Transfus Med Rev,2020,34(4):250-257.
[16] SCHMIDT A E,REFAAI M A,COPPAGE M.HLA-mediated platelet refractoriness[J].Am J Clin Pathol,2019,151(4):353-363.
[17] BLANDIN L,DOUGÉ A,FAYARD A,et al.Platelet transfusion refractoriness and anti-HLA immunization[J]. Transfusion,2021,61(6):1700-1704.
[18] VASSALLO R R.Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients[J]. Immunohematology,2009,25(3):119-124.
[19] TRIULZI D J,KLEINMAN S,KAKAIYA R M,et al.The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors:implications for a transfusion-related acute lung injury risk reduction strategy[J]. Transfusion,2009,49(9):1825-1835.
[20] KAO K J,COOK D J,SCORNIK J C.Quantitative analysis of platelet surface HLA by W6/32 anti-HLA monoclonal antibody[J]. Blood,1986,68(3):627-632.
[21] RIJKERS M,SCHMIDT D,LU N N,et al.Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets[J]. Haematologica,2019,104(2):403-416.
[22] COHN C S.Platelet transfusion refractoriness:how do I diagnose and manage?[J].Hematology Am Soc Hematol Educ Program,2020,2020(1):527-532.
[23] NICULITE C M,ENCIU A M,HINESCU M E.CD 36:focus on epigenetic and post-transcriptional regulation[J]. Front Genet,2019,10:680.
[24] ZHANG Y,ZANG J,WANG B,et al.CD36 genotype associated with ischemic stroke in Chinese Han[J]. Int J Clin Exp Med,2015,8(9):16149-16157.
[25] AUBUCHON J P,LEACH M F.Investigating the possibility of drug-dependent platelet antibodies[J]. Immunohematology,2009,25(3):136-140.
[26] LEACH M F,COOPER L K,AUBUCHON J P.Detection of drug-dependent,platelet-reactive antibodies by solid-phase red cell adherence assays[J].Br J Haematol,1997,97(4):755-761.
[27] CURTIS B R.Drug-induced immune thrombocytopenia:incidence,clinical features,laboratory testing,and pathogenic mechanisms[J]. Immunohematology,2014,30(2):55-65.
[28] REESE J A,LI X N,HAUBEN M,et al.Identifying drugs that cause acute thrombocytopenia:an analysis using 3 distinct methods[J].Blood,2010,116(12):2127-2133.
[29] KAM T,ALEXANDER M.Drug-induced immune thrombocytopenia[J].J Pharm Pract,2014,27(5):430-439.
[30] ARTHUR C M,PATEL S R,SULLIVAN H C,et al.CD8+ T cells mediate antibody-independent platelet clearance in mice[J]. Blood,2016,127(14):1823-1827.
[31] DALY P A,SCHIFFER C A,AISNER J,et al.Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations[J]. JAMA,1980,243(5):435-438.
[32] 朱传福,宋永红,刘金玲,等.山东省区域性血小板供者信息网络建设及应用[J].临床输血与检验,2017,19(5):518-520.
[33] TRIAL to Reduce Alloimmunization to Platelets Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions[J]. N Engl J Med,1997,337(26):1861-1869.
[34] GAVVA C,BARROSO J,GERNSHEIMER T,et al.Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients[J]. Transfusion,2019,59(7):2276-2281.
[35] DUQUESNOY R J.Structural epitope matching for HLA-alloimmunized thrombocytopenic patients:a new strategy to provide more effective platelet transfusion support?[J]. Transfusion,2008,48(2):221-227.
[36] Duquesnoy R J.HLA matching at the epitope level:the way to go[J]. Clin Transpl,2013:2013;441-2013;451.
[37] MARSH J C,STANWORTH S J,PANKHURST L A,et al.An epitope-based approach of HLA-matched platelets for transfusion:a noninferiority crossover randomized trial[J]. Blood,2021,137(3):310-322.
[38] SARIS A,TOMSON B,BRAND A,et al.Platelets from donors with consistently low HLA-B8,-B12,or-B35 expression do not undergo antibody-mediated internalization[J]. Blood,2018,131(1):144-152.
[39] NOVOTNY V M,DOXIADIS I N,VAN DOORN R,et al.The kinetics of HLA class I elution and the relevance for the use of HLA-eluted platelet transfusions[J].Br J Haematol,1996,95(2):416-422.
[40] VO P,PUREV E,WEST K A,et al.A pilot trial of complement inhibition using eculizumab to overcome platelet transfusion refractoriness in human leukocyte antigen allo-immunized patients[J]. Br J Haematol,2020,189(3):551-558. |
